Document Detail

Slowing nephropathy progression: focus on proteinuria reduction.
MedLine Citation:
PMID:  18178794     Owner:  NLM     Status:  MEDLINE    
Blood pressure control reduces decline of kidney function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer renoprotection to a small extent beyond that attributable to blood pressure lowering. These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits.
George L Bakris
Related Documents :
2808894 - Continuous high volume venous-venous haemofiltration in acute renal failure.
7631844 - Effects of renal denervation on cardiovascular response to furosemide in conscious lambs.
15854154 - Long-term recording of sympathetic nerve activity: the new frontier in understanding th...
1633364 - Hypertension in an adult with unilateral renal dysplasia.
16533634 - Initial ventilation strategies during newborn resuscitation.
468404 - An in vitro comparison of capillary flow dialyzer performances on a single needle syste...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical journal of the American Society of Nephrology : CJASN     Volume:  3 Suppl 1     ISSN:  1555-905X     ISO Abbreviation:  Clin J Am Soc Nephrol     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-07     Completed Date:  2008-03-05     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  101271570     Medline TA:  Clin J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S3-10     Citation Subset:  IM    
Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure / drug effects
Cardiovascular Diseases / etiology
Diabetes Complications
Disease Progression
Kidney Diseases / drug therapy*,  etiology,  physiopathology*,  urine
Proteinuria / drug therapy*
Risk Factors
Time Factors
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers...
Next Document:  Recent advances in the prevention and management of intradialytic hypotension.